Development and Application of Ligand-Exchange Reaction Method for the Determination of Clonazepam
Purpose: This paper presents an improved kinetic-spectrophotometric procedure for determining clonazepam (CZP) in pharmaceutical formulations and human serum.
Methods: The method is based on ligand-exchange reaction. The reaction was followed spectrophotometrically by measuring the rate of change of absorbance at 425 nm in ethanolic sodium hydroxide solution.
Results: The optimum operating conditions for reagent concentrations and temperature were established. Linear calibration curve was obtained in the range of 0.32 - 4.10 μg mL-1. The optimized conditions yielded a theoretical detection limit of 0.24 μg mL-1 based on the 3.3So criterion, where S0 is standard deviation of the calibration line. The interference of certain drugs, foreign ions and amino acids on the reaction rate were studied in order to assess the selectivity of the method.
Conclusion: The developed method is sensitive, accurate and reproducible and could be used for routine anlysis of clonazepam in pharmaceutical preparations and serum samples.
Keywords: Clonazepam, Ligand-exchange reaction, Kinetic spectrometry, Validation, Pharmaceutical preparation, Human serum
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.